Clinical effects of Pemetrexed combined tegafur in the treatment of advanced breast cancer
10.3760/cma.j.issn.1008-6315.2013.04.001
- VernacularTitle:培美曲塞联合替吉奥治疗晚期乳腺癌的效果观察
- Author:
Ruixue QI
;
Tiankui QIAO
;
Shu WANG
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Pemetrexed;
Tegafur;
Chemotherapy
- From:
Clinical Medicine of China
2013;(4):337-339
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicity of anthracycline and taxane combination regimen in the treatment of advanced breast cancer in patients who were previously treated with anthracycline and taxane.Methods Twenty-six patients who previously failed to respond to anthracycline and taxane based chemotherapy received pemetrexed and tegafur combination regimen (pemetrexed:500 mg/m2,ivgtt on the first day; tegafur:80 mg/(m2 · d),twice daily during day 1-14).The regimen was repeated at least two cycles of three weeks each and the clinical response was recorded at two weeks after treatment.Results Of the 26 patients,he tumor control rate was 65.3％ (17/26),and the overall response rate was 46.2％ (12/26),including 3 patients with complete remission and 9 patients with partial remission.The symptoms were stable in 5 patients and improved in 9 patients.There was no severe complications or death observed.The most frequent treatment-related adverse events were myelosuppression,nausea,vomitting,rash and hepatic function impairment.Conclusion Pemetrexed combined with tegafur in the treatment of patients with advanced metastatic breast cancer who did not respond to anthracycline and taxane treatment is effective with minimal adverse reactions and can be tolerated by patients.
